This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Study Type
OBSERVATIONAL
Enrollment
150
During routine blood sample collection, additional blood will be drawn for analysis of ctDNA and to collect Circulating Tumor Cells.
Erasmus MC
Rotterdam, South Holland, Netherlands
RECRUITINGOverall survival
Overall survival will be defined as the time from inclusion to death from any cause.
Time frame: 44 months
Progression free survival
Progression free survival will be defined as clinical, radiological or PSA progression according to Prostate Cancer Working Group 3 (PCWG3) or death, whichever occurs first.
Time frame: 44 months
Heterogeneity of PSMA-positivity
Exploring heterogeneity of PSMA-positivity in circulating tumor cells (CTC) prior to treatment with Lutetium-PSMA.
Time frame: 44 months
Effect of CTC PSMA expression on response to treatment.
Exploring whether there is an association between the fraction of PSMA positive CTCs and response to Lutetium-PSMA treatment.
Time frame: 44 months
Effect of biomarkers in blood on response to treatment.
Exploring the association between biomarkers in blood and response to treatment
Time frame: 44 months
PSMA-PET scan data and response to treatment.
Exploring associations between PSMA-PET and therapy scans and response to treatment.
Time frame: 44 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.